Clinical Trial Update: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

The Phase 1 trial of GNC-035, a tetra-specific antibody, for locally advanced or metastatic solid tumors has been withdrawn. Breast cancer was listed among the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GNC-035

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Breast Cancer, Solid Tumor | Phase 1 | Status: WITHDRAWN